ERBB2 and breast carcinoma: Furthermore, the overexpression of HER2 triggers the HER2-IL-6- signal transducer and activator of transcription 3 (STAT3) signaling cascade, which stimulates breast cancer stem cells to self-renew and develop resistance to anti-HER2 therapy.62